Alpha-2-HS-glycoprotein

Taxonomy

• Homo sapiens (Human)

Protein

• Alpha-2-HS-glycoprotein / Homo sapiens    P02765

Source

• Blood Plasma (UBERON_0001969)  
• Blood Serum (UBERON_0001977)  
• Mammary Gland (UBERON_0001911)  
• Urine (UBERON_0001088)  
• Cerebrospinal Fluid Secretion (GO_0033326)  

Reported structure

• N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• N-Linked / Complex / Structure 3041
• N-Linked / Complex / Structure 644
• N-Linked / Complex / NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• N-Linked / Undefined core / NeuAc(??-?)HexNAc(??-?)HexNAc(??-?)Hex(??-?)[NeuAc(??-?)Hex(??-?)HexNAc(??-?)Hex(??-?)]Hex(??-?)HexNAc(??-?)[Fuc(??-?)]HexNAc
• O-Linked / Core 1 / Gal(b1-3)[Neu5Ac(?2-?)]GalNAc(a1-
• O-Linked / Core 1 / NeuAc(a2-3)Gal(b1-3)GalNAc
• O-Linked / Core 1 / Neu5Ac(?2-?)Gal(b1-3)[Neu5Ac(?2-?)]GalNAc(a1-

Composition

• Hex:1 HexNAc:1 (avg mass : 383.3527 )
• Hex:1 HexNAc:1 NeuAc:1 (avg mass : 674.6106 )
• Hex:1 HexNAc:1 NeuAc:2 (avg mass : 965.8685 )
• Hex:3 HexNAc:6 dHex:2 NeuGc:1 (avg mass : 2323.1558 )
• Hex:4 HexNAc:3 NeuAc:1 (avg mass : 1567.4278 )
• Hex:4 HexNAc:4 NeuAc:1 (avg mass : 1770.6228 )
• Hex:4 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 1916.7658 )
• Hex:4 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2062.9088 )
• Hex:4 HexNAc:5 NeuAc:1 NeuGc:1 (avg mass : 2281.0751 )
• Hex:4 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2411.2187 )
• Hex:4 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2266.1038 )
• Hex:4 HexNAc:6 dHex:2 (avg mass : 2178.0409 )
• Hex:4 HexNAc:7 dHex:1 (avg mass : 2235.0929 )
• Hex:5 HexNAc:4 (avg mass : 1641.5073 )
• Hex:5 HexNAc:4 NeuGc:1 (avg mass : 1948.7646 )
• Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
• Hex:5 HexNAc:4 NeuAc:2 (avg mass : 2224.0231 )
• Hex:5 HexNAc:4 dHex:1 (avg mass : 1787.6503 )
• Hex:5 HexNAc:4 dHex:1 NeuGc:2 (avg mass : 2402.1649 )
• Hex:5 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2078.9082 )
• Hex:5 HexNAc:4 dHex:1 NeuAc:1 NeuGc:1 (avg mass : 2386.1655 )
• Hex:5 HexNAc:4 dHex:1 NeuAc:2 (avg mass : 2370.1661 )
• Hex:5 HexNAc:4 dHex:2 (avg mass : 1933.7933 )
• Hex:5 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2225.0512 )
• Hex:5 HexNAc:4 dHex:3 NeuAc:1 (avg mass : 2371.1942 )
• Hex:5 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2282.1032 )
• Hex:5 HexNAc:6 dHex:1 (avg mass : 2194.0403 )
• Hex:5 HexNAc:8 (avg mass : 2454.2873 )
• Hex:6 HexNAc:4 NeuAc:1 (avg mass : 2094.9076 )
• Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
• Hex:6 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2241.0506 )
• Hex:6 HexNAc:4 dHex:2 (avg mass : 2095.9357 )
• Hex:6 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2387.1936 )
• Hex:6 HexNAc:4 dHex:3 (avg mass : 2242.0787 )
• Hex:6 HexNAc:5 (avg mass : 2006.8447 )
• Hex:6 HexNAc:5 NeuAc:1 (avg mass : 2298.1026 )
• Hex:6 HexNAc:5 NeuAc:2 (avg mass : 2589.3605 )
• Hex:6 HexNAc:5 NeuAc:3 (avg mass : 2880.6184 )
• Hex:6 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2735.5035 )
• Hex:6 HexNAc:5 dHex:1 NeuAc:3 (avg mass : 3026.7614 )
• Hex:6 HexNAc:5 dHex:2 (avg mass : 2299.1307 )
• Hex:6 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2590.3886 )
• Hex:6 HexNAc:5 dHex:2 NeuAc:2 (avg mass : 2881.6465 )
• Hex:7 HexNAc:3 dHex:1 NeuAc:1 (avg mass : 2199.998 )
• Hex:7 HexNAc:4 dHex:2 (avg mass : 2258.0781 )
• Hex:7 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2897.6459 )
• Hex:7 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2809.583 )
• Hex:8 HexNAc:5 dHex:4 (avg mass : 2915.7015 )
• Hex:8 HexNAc:7 NeuGc:1 (avg mass : 3044.7768 )
• Hex:9 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 3425.1257 )
• Hex:12 HexNAc:2 (avg mass : 2370.1141 )

Disease

• Cancer, breast (DOID:1612)
• Oral squamous cell carcinoma (DOID:0050866)
• Prostate cancer (DOID:10283)

Reference

• Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
• Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
• Tongue Cancer Patients Can be Distinguished from Healthy Controls by Specific N-Glycopeptides Found in Serum. (2018 - Mayank Saraswat, Antti Mäkitie, Tiialotta Tohmola, Amy Dickinson, Shruti Saraswat, Sakari Joenväärä, Suvi Renkonen) / Status : Reviewed
• Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
• Large-scale intact glycopeptide identification by Mascot database search (2018 - Ravi Chand Bollineni, Christian Jeffrey Koehler, Randi Elin Gislefoss, Jan Haug Anonsen, Bernd Thiede) / Status : Unreviewed
• Glycomic analysis of high density lipoprotein shows a highly sialylated particle (2014 - Huang J1, Lee H, Zivkovic AM, Smilowitz JT, Rivera N, German JB, Lebrilla CB) / Status : Reviewed
• Selective glycopeptide profiling by acetone enrichment and LC/MS (2014 - Takakura D, Harazono A, Hashii N, Kawasaki N) / Status : Reviewed
• Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls (2014 - Kontro H, Joenväärä S, Haglund C, Renkonen R) / Status : Reviewed
• Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD (2012 - Halim A, Nilsson J, Rüetschi U, Hesse C, Larson G) / Status : Reviewed
• Enrichment of glycopeptides for glycan structure and attachment site identification (2009 - Nilsson J, Rüetschi U, Halim A, Hesse C, Carlsohn E, Brinkmalm G, Larson G.) / Status : Reviewed
• Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry (2008 - Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T) / Status : Reviewed
• Structure of the N- and O-glycans of the A-chain of human plasma alpha 2HS-glycoprotein as deduced from the chemical compositions of the derivatives prepared by stepwise degradation with exoglycosidases. (1992 - Watzlawick H, Walsh M, Yoshioka Y, Schmid K, Brossmer R) / Status : Reviewed
• Characterization of the B-chain of human plasma alpha 2HS-glycoprotein. The complete amino acid sequence and primary structure of its heteroglycan. (1983 - Gejyo F, Chang J, Brgi W, Schmid K, Offner G, Troxler R, Van Halbeek H, Dorland L, Gerwig G, Vliegenthart J) / Status : Reviewed

Reported glycosite

• Alpha-2-HS-glycoprotein / Homo sapiens
  •        Asn-156
  •        Asn-172
  •        Asn-176
  •        Thr-256
  •        Thr-270
  •        Ser-346

Mass spectrometry observed peptide

• VCQDCPLLAPLNDTR (15aa)
  •    P02765    Asn-156
• KVCQDCPLLAPLNDTR (16aa)
  •    P02765    Asn-156
• VCQDCPLLAPLNDTRVVHAAK (21aa)
  •    P02765    Asn-156
• VCQDCPIIAPINDTR (15aa)
  •    P02765    Asn-156
• AALAAFNAQNNGSNFQLEEISR (22aa)
  •    P02765    Asn-172
• AALAAFNAQNNGSNFQLEEISR (22aa)
  •    P02765    Asn-176
• AAFNAQNNGSNFQLEEISR (19aa)
  •    P02765    Asn-176
• NAQNNGSNFQLEEISR (16aa)
  •    P02765    Asn-176